<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>314-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BACLOFEN" rxcui="1292">
<ATC code="M03BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of aggravation of the Parkinsonian syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>314-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="1431589">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the levodopa</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>314-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of orthostatic hypotension 

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>314-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHYLDOPA" rxcui="6876">
<ATC code="C02AB" />
<ATC code="C02LB" />
<ATC code="C02AB01" />
<ATC code="C02LB01" />
<ATC code="C02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly decrease of the doses of levodopa.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>314-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTIEMITIC NEUROLEPTICS" code="A03FA-001" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism between the levodopa and the neuroleptic 

</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Use an antiemitic without extrapyramidal effects.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>314-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)" code="N05A-001" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism between the levodopa and the neuroleptics</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>With a parkinsons patient, use the minimum effective dosees of each of the two medications. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>314-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RESERPINE" rxcui="9260">
<ATC code="C02AA02" />
<ATC code="C02LA01" />
<ATC code="C02LA51" />
<ATC code="C02LA71" />
<ATC code="C02AA52" />
</DRUG>
</DRUG2>
<DESCRIPTION>Inhibition of the effects of the levodopa</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>314-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SPIRAMYCIN" rxcui="9991">
<ATC code="J01RA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>When administered with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the levodopa. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>314-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TETRABENAZINE" rxcui="10390">
<ATC code="N07XX06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reciprocal antagonism between the levodopa and the tetrabenazine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
